Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Treatments targeting inotropy

Open access
Maack, Christoph, Eschenhagen, Thomas, Hamdani, Nazha, Heinzel, Frank R, Lyon, Alexander R, Manstein, Dietmar J, Metzger, Joseph, Papp, Zoltán, Tocchetti, Carlo G, Yilmaz, M Birhan, Anker, Stefan D, Balligand, Jean-Luc, Bauersachs, Johann, Brutsaert, Dirk, Carrier, Lucie, Chlopicki, Stefan, Cleland, John G, de Boer, Rudolf A, Dietl, Alexander, Fischmeister, Rodolphe, Harjola, Veli-Pekka, Heymans, Stephane, Hilfiker-Kleiner, Denise, Holzmeister, Johannes, de Keulenaer, Gilles, Limongelli, Giuseppe, Linke, Wolfgang A, Lund, Lars H, Masip, Josep, Metra, Marco, Mueller, Christian, Pieske, Burkert, Ponikowski, Piotr, Ristić, Arsen, Ruschitzka, Frank, Seferović, Petar M, Skouri, Hadi, Zimmermann, Wolfram H, Mebazaa, Alexandre·2019·European Heart Journal

Abstract

Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesterase-inhibitors, is associated with increased mortality. Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca2+. Although meta-analyses of smaller trials suggested that levosimendan is associated with a better outcome than dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv mecarbil, Phase II clinical trials suggest a favourable haemodynamic profile in patients with acute and chronic HF, and a Phase III morbidity/mortality trial in patients with chronic HF has recently begun. Here, we review the pathophysiological basis of systolic dysfunction in patients with HF and the mechanisms through which different inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen species production in mitochondria are intimately linked to the processes of excitation–contraction coupling, we also discuss the impact of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this position paper should help identify novel targets for treatments that could not only safely improve systolic and diastolic function acutely, but potentially also myocardial structure and function over a longer-term.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehy600

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 229

Metadata

Authors
Maack, C., Eschenhagen, T., Hamdani, N., Heinzel, F. R., Lyon, A. R., Manstein, D. J., Metzger, J., Papp, Z., Tocchetti, C. G., Yilmaz, M. B., Anker, S. D., Balligand, J.-L., Bauersachs, J., Brutsaert, D., Carrier, L., Chlopicki, S., Cleland, J. G., de Boer, R. A., Dietl, A., Fischmeister, R., Harjola, V.-P., Heymans, S., Hilfiker-Kleiner, D., Holzmeister, J., de Keulenaer, G., Limongelli, G., Linke, W. A., Lund, L. H., Masip, J., Metra, M., Mueller, C., Pieske, B., Ponikowski, P., Ristić, A., Ruschitzka, F., Seferović, P. M., Skouri, H., Zimmermann, W. H., & Mebazaa, A.
Venue
European Heart Journal
Published
2018-10-08
Volume
40
Issue
44
Pages
3626-3644
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2897286847
Cited by
229
References
8
FWCI
10.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatments targeting inotropy. https://app.cochat.ai/papers/10.1093/eurheartj/ehy600
The paper
Maack, C., Eschenhagen, T., Hamdani, N., Heinzel, F. R., Lyon, A. R., Manstein, D. J., Metzger, J., Papp, Z., Tocchetti, C. G., Yilmaz, M. B., Anker, S. D., Balligand, J.-L., Bauersachs, J., Brutsaert, D., Carrier, L., Chlopicki, S., Cleland, J. G., de Boer, R. A., Dietl, A., . . . Mebazaa, A. (2019). Treatments targeting inotropy. European Heart Journal. https://doi.org/10.1093/eurheartj/ehy600

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.